In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Clearside Biomedical (CLSD), with a price target of $4. The company’s shares opened today at $1.50, close to its 52-week low of $0.99.
According to TipRanks.com, Moussatos ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.5% and a 38.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Clearside Biomedical is a Moderate Buy with an average price target of $4.
See today’s analyst top recommended stocks >>
Based on Clearside Biomedical’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $21.64 million. In comparison, last year the company had a GAAP net loss of $16.49 million.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CLSD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy.
